GILD Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 19.72% compared to Gilead Sciences's net margin of 50.24%. Gilead Sciences's return on equity of 32.29% beat Johnson & Johnson's return on equity of 30.18%.

Gilead Sciences has a consensus price target of $116.85, signalling upside risk potential of 4.24%. On the other hand Johnson & Johnson has an analysts' consensus of $169.14 which suggests that it could grow by 7.86%. Given that Johnson & Johnson has higher upside potential than Gilead Sciences, analysts believe Johnson & Johnson is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.290, which suggesting that the stock is 71.014% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.579%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.78%. Johnson & Johnson offers a yield of 3.2% to investors and pays a quarterly dividend of $1.30 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $6.7B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Gilead Sciences's net income of $1.3B is lower than Johnson & Johnson's net income of $11B. Notably, Gilead Sciences's price-to-earnings ratio is 23.60x while Johnson & Johnson's PE ratio is 17.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.92x versus 4.26x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 19.72% compared to Gilead Sciences's net margin of 21.68%. Gilead Sciences's return on equity of 32.29% beat Eli Lilly and's return on equity of 78.25%.

Gilead Sciences has a consensus price target of $116.85, signalling upside risk potential of 4.24%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 19.13%. Given that Eli Lilly and has higher upside potential than Gilead Sciences, analysts believe Eli Lilly and is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.290, which suggesting that the stock is 71.014% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.78%. Eli Lilly and offers a yield of 0.7% to investors and pays a quarterly dividend of $1.50 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $6.7B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Gilead Sciences's net income of $1.3B is lower than Eli Lilly and's net income of $2.8B. Notably, Gilead Sciences's price-to-earnings ratio is 23.60x while Eli Lilly and's PE ratio is 65.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.92x versus 14.73x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 19.72% compared to Gilead Sciences's net margin of 32.71%. Gilead Sciences's return on equity of 32.29% beat Merck &'s return on equity of 39.02%.

Gilead Sciences has a consensus price target of $116.85, signalling upside risk potential of 4.24%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 21.65%. Given that Merck & has higher upside potential than Gilead Sciences, analysts believe Merck & is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.290, which suggesting that the stock is 71.014% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.78%. Merck & offers a yield of 3.83% to investors and pays a quarterly dividend of $0.81 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

Gilead Sciences quarterly revenues are $6.7B, which are smaller than Merck & quarterly revenues of $15.5B. Gilead Sciences's net income of $1.3B is lower than Merck &'s net income of $5.1B. Notably, Gilead Sciences's price-to-earnings ratio is 23.60x while Merck &'s PE ratio is 12.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.92x versus 3.32x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 19.72% compared to Gilead Sciences's net margin of -907.48%. Gilead Sciences's return on equity of 32.29% beat Moderna's return on equity of -29.23%.

Gilead Sciences has a consensus price target of $116.85, signalling upside risk potential of 4.24%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 44.79%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Gilead Sciences has a beta of 0.290, which suggesting that the stock is 71.014% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Gilead Sciences has a quarterly dividend of $0.79 per share corresponding to a yield of 2.78%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gilead Sciences pays 816.25% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Gilead Sciences quarterly revenues are $6.7B, which are larger than Moderna quarterly revenues of $107M. Gilead Sciences's net income of $1.3B is higher than Moderna's net income of -$971M. Notably, Gilead Sciences's price-to-earnings ratio is 23.60x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gilead Sciences is 4.92x versus 4.07x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.